Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC).
IC50&Target
IC50: 9 nM (HIF-2α)
体外研究
Belzutifan (PT2977) potently and dose-dependently reduces mRNA levels of human cyclin D1, a target gene regulated by HIF-2α, and leads to rapid and dose-dependent reduction in EPO expression.
分子式
C17H12F3NO4S
分子量
383.34
CAS号
1672668-24-4
运输条件
Room temperature in continental US; may vary elsewhere.